Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tsumura & Co ( (JP:4540) ) has shared an announcement.
Tsumura & Co. has announced the completion of an interim review of its consolidated financial results for the third quarter ending March 31, 2025. The review, conducted by certified public accountants, confirmed no changes to the financial statements released earlier. This announcement is part of the company’s ongoing efforts related to a share offering, highlighting its commitment to transparency and compliance with financial regulations.
More about Tsumura & Co
Tsumura & Co. operates in the pharmaceutical industry, primarily focusing on the production and distribution of traditional Japanese Kampo medicines. The company is listed on the TSE Prime Market and is headquartered in Tokyo, Japan.
YTD Price Performance: -4.59%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.19B
For a thorough assessment of 4540 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue